Default

Allergy and immunology

Anaesthesia

Basic research

Cardiovascular medicine

Complementary medicine and alternative therapies

Critical care / intensive care

Dentistry / oral medicine

Dermatology

Emergency medicine

Endocrinology

Epidemiology

Ethics

Evidence-based medicine

Gastroenterology

Genetics

Geriatric medicine / aging

Haematology / blood transfusion

Health economics

Health policy

History of medicine

Infectious diseases

Internal medicine

Laboratory medicine

Medical education

Medical informatics

Neurology

Nursing

Nutrition and metabolism

Obstetrics and gynaecology

Occupational and environmental medicine

Oncology

Ophthalmology

Organisation of health care

Otolaryngology / head and neck surgery

Paediatrics

Palliative care

Pathology

Patient-physician relationship

Pharmacology and therapeutics

Primary care, family medicine

Psychiatry and psychotherapy

Psychosomatics

Public health

Quality of care

Radiology

Rehabilitation medicine

Renal medicine

Respiratory medicine

Rheumatology

Sexual medicine

Sports medicine

Statistics and research methods

Surgery

Transplantation

Travel medicine

Urology

Ops! No article found. Reset filter

Gout management in Swiss primary care – a retrospective observational study

Original article
Meier R, di Gangi S, Valeri F, Rosemann T, Zechmann S
Swiss Med Wkly. 2020;150:w20209

Swiss gout patients receive comprehensive treatment, which is reflected in a high number of patients treated with urate-lowering therapy, laboratory tests per person and a high treatment success rate, although there is no systematic approach to the treatment of gout.

Should systemic sclerosis be recognised as an occupational disease in Switzerland?

Original article
Schmid M, Grolimund Berset D, Krief P, Zyska Cherix A, Danuser B, Rinaldo M
Swiss Med Wkly. 2020;150:w20193

Although the aetiology of systemic sclerosis is not yet completely understood, epidemiological studies have identified several occupational factors, such as exposure to silica, solvents or vibration, that contribute to its development.

A large-scale assessment of the healthcare burden of adhesive capsulitis of the shoulder joint

Original article
Bouaicha S, Wieser K, Kriechling P, Scholz-Odermatt SM
Swiss Med Wkly. 2020;150:w20188

Frozen shoulder is a poorly understood pathological entity which is characterised by a painful and stiff shoulder. No current epidemiological data with respect to frozen shoulder-induced direct and indirect costs to the Swiss national healthcare system are available.

Importance of osteocyte-mediated regulation of bone remodelling in inflammatory bone disease

Review article: Biomedical intelligence
Intemann J, De Gorter DJJ, Naylor AJ, Dankbar B, Wehmeyer C
Swiss Med Wkly. 2020;150:w20187

Continuous bone remodelling is required to replace old bone tissue and to repair bone micro-cracks. In adults it has been estimated that 10% of bone is replaced every year and that this is crucial for maintenance of a healthy skeleton.

A simple guide to the interpretation of the significance of the association of a disease with a particular HLA allele

Review article: Biomedical intelligence
Winchester R
Swiss Med Wkly. 2019;149:w20128

The impressive survival advantage of the adaptive immune system comes at the cost of autoimmunity and autoimmune disease because of the self-selected character of the adaptive immune system’s T cell repertoires.

The target uric acid level in multimorbid patients with gout is difficult to achieve: data from a longitudinal Swiss single-centre cohort

Original article
Ankli B, Berger CT, Haeni N, Kyburz D, Hügle T, So AKL, Daikeler T
Swiss Med Wkly. 2019;149:w20121

Despite the huge impact of gout on health, its treatment remains unsatisfactory. Subsets of patients are paticularly difficult to treat, owing to existing comorbidities and polypharmacy.

Behçet’s syndrome: clinical presentation and prevalence in Switzerland

Original article
Villiger RA, Stefanski AL, Grobéty V, Adler S, Villiger PM
Swiss Med Wkly. 2019;149:w20072

Behçet’s syndrome is a rare systemic autoimmune/autoinflammatory disease. In Switzerland there are no published data regarding the prevalence of Behçet’s syndrome, its manifestations or its management.

Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland

Original article
von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger PM, Vallelian F, Schaer DJ, Mueller RB
Swiss Med Wkly. 2019;149:w20022

This study provides real-world insight into belimumab use in clinical practice in Switzerland. In line with findings from other countries, Swiss patients with SLE who received belimumab demonstrated clinical and serological improvements in SLE and a reduction in corticosteroid use after six months of treatment.

The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis

Review article: Biomedical intelligence
Berger CT, Sommer G, Aschwanden M, Staub D, Rottenburger C, Daikeler T
Swiss Med Wkly. 2018;148:w14661

The manifestations of giant cell arteritis can be variable. About a third of large-vessel giant cell arteritis patients have no sonographic evidence of temporal vasculitis, and more than half have normal histology of the temporal artery.

The Expanded Risk Score in Rheumatoid Arthritis: performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthritis

Original article
Salaffi F, Carotti M, Di Carlo M, Tardella M, Lato V, Becciolini A, Favalli EG, Giovagnoni A
Swiss Med Wkly. 2018;148:w14656

The increased risk of cardiovascular disease has emerged as a major issue in patients with rheumatoid arthritis – it has been estimated that the cardiovascular disease burden in rheumatoid arthritis is comparable to that of diabetes mellitus.

Verpassen Sie keinen Artikel!

close